Sign in

CIK 0001158780

  • Non-accelerated filer
  • Smaller reporting company
Ticker
PLUR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Jun 30
Incorporated
NV
Entity type
Operating
EIN
980351734
Phone
+972 747107171
Business address
MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, Israel
Former names
PLURISTEM THERAPEUTICS INC, PLURISTEM LIFE SYSTEMS INC, AI SOFTWARE INC
  1. 4 Grant or award President, COO, CFO acquired 200,000 shares (grant or award)
  2. 4 Grant or award CEO & Chairman acquired 200,000 shares (grant or award)
  3. 4 Grant or award Director acquired 49,000 shares (grant or award)
  4. 4 Grant or award Director acquired 49,000 shares (grant or award)
  5. 4 Grant or award Director acquired 35,000 shares (grant or award)
  6. 4 Grant or award Director acquired 48,000 shares (grant or award)
  7. 4 Grant or award Director acquired 35,000 shares (grant or award)
  8. 4 Grant or award Director acquired 35,000 shares (grant or award)
  9. 4 Grant or award Director acquired 49,000 shares (grant or award)
  10. 4 Grant or award Chief Financial Officer acquired 48,332 shares (grant or award)
  11. 4 Open-market buy CEO & Chairman bought 13,000 shares at an average $2.64 ($34,255)
  12. 4 Open-market buy COO & President bought 11,000 shares at an average $2.62 ($28,790)
  13. 4 Grant or award COO & President acquired 11,499 shares (grant or award)
  14. 4 Open-market buy COO & President bought 11,000 shares at $2.95 ($32,450)
  15. 4 Open-market buy CEO & Chairman bought 5,000 shares at $2.92 ($14,600)
  16. 4 Open-market buy CEO & Chairman bought 5,000 shares at an average $2.96 ($14,775)
  17. 4 Open-market buy Director bought 5,000 shares at an average $2.82 ($14,100)
  18. 4 Open-market buy CEO & Chairman bought 15,000 shares at $2.84 ($42,600)
  19. 4 Open-market buy Chief Financial Officer bought 1,250 shares at $2.75 ($3,438)
  20. 4 Open-market buy Chief Financial Officer bought 3,478 shares at $2.84 ($9,878)

Page 8 of 18 · 352 filings